Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea
Hui-Jeong Hwang, Minji Kim, Ji Eun Jun, Dong Keon Yon · 2023
Read Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea by Hui-Jeong Hwang, Minji Kim, Ji Eun Jun, Dong Keon Yon (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10709414.txt.
Description
Hui-Jeong Hwang and three colleagues published a cohort study in two thousand twenty-three on diabetes drugs during cancer chemotherapy. A class of sugar-lowering drugs, SGLT2 inhibitors, protected animal hearts against a common chemotherapy family. Human evidence was missing.
Using nationwide Korean records, the team emulated a trial among over eighty-one thousand chemotherapy patients. About seven hundred eighty had diabetes and took the drug class. After matching, those patients had far fewer combined events of heart failure, heart attack, stroke, and death than both non-diabetic patients and diabetics on other drugs. The authors say the drugs may shield the heart during treatment, while noting the design cannot prove cause.
Catalog record
| CREATOR | Hui-Jeong Hwang, Minji Kim, Ji Eun Jun, Dong Keon Yon |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |